CASI Pharmaceuticals, Inc.
Biopharmaceutical firm developing therapeutics for organ transplant and autoimmune diseases.
CASI | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1701-1702, CHINA CENTRAL OFFICE TOWER 1, 100025 BEIJING
- Sector:
- Manufacturing
Description
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for organ transplantation and autoimmune diseases. The company's lead program is centered on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to address antibody-mediated rejection (AMR) in organ transplant recipients, a significant unmet medical need with no currently approved treatments. The mechanism of CID-103 targets B memory cells, plasmablasts, and persistent plasma cells that can contribute to organ rejection. The company is also exploring the potential of this anti-CD38 approach for treating various autoimmune diseases, such as immune thrombocytopenia (ITP).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CASI Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CASI Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CASI Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
